This panel discussion highlights that NMOSD care still depends heavily on clinical judgment, as gaps in pathophysiology, monitoring tools, and long-term treatment strategies persist.
This expert panel discussion explores the current challenges in understanding and managing neuromyelitis optica spectrum disorder (NMOSD). Bringing together clinical perspectives, the conversation highlights gaps in pathophysiology, limitations in monitoring tools, and ongoing uncertainties in long-term treatment strategies. Despite advances in biomarkers and therapies, real-world decision-making remains largely driven by clinical experience.
Key Insights from the Lecture:
- Antibodies alone are not sufficient to cause disease
- Clinical context remains essential
- T cells play a critical role in disease activation
- Pathophysiology is still not fully understood
- Monitoring treatment response is challenging
- GFAP shows promise but remains limited
- MRI has limited utility compared to MS
- Clinical follow-up remains the gold standard
- Long-term treatment duration is still unclear
- Collaboration is essential in rare diseases
“Multiple Sclerosis and pregnancy: from planning to postpartum”.
Please subscribe to watch.
About the speaker:
Jelena Drulovic, Nikolaos Grigoriadis, Melinda Magyari
Media
Details
We value your opinion.
